LINTEX
920106
LINGOOD
833284
NTGEC
870436
4
CG MED EQUIP.
838810
5
Jiayu Holding
300117
US Stock MarketDetailed Quotes
MGRX Mangoceuticals
- 4.130
- -0.075-1.78%
Close Feb 28 16:00 ET
- 4.130
- 0.0000.00%
Post 20:01 ET
20.19MMarket Cap-0.95P/E (TTM)
4.420High3.895Low59.70KVolume4.090Open4.205Pre Close250.09KTurnover1.62%Turnover RatioLossP/E (Static)4.89MShares16.80052wk High1.51P/B15.26MFloat Cap2.07052wk Low--Dividend TTM3.69MShs Float65.550Historical High--Div YieldTTM12.49%Amplitude2.070Historical Low4.188Avg Price1Lot Size
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
Mangoceuticals Stock Forum
Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
Thursday, 20th February at 7:00 am
Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products via a secure telemedicine platform under the brand MangoRx, proudly annou...
Mangoceuticals Announces the Launch of “Peachesrx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
Revolutionary Water-Based Solution Shows Promise in Fighting Bird Flu Crisis - Phase I Results Reveal Major Breakthrough
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
Thursday, 6th February at 7:00 am
Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedic...
Major H1N1 Treatment Success: Mangoceuticals' Novel Antiviral Shows Promise Against Bird Flu
Benzinga· 1 min ago
No comment yet